Concord Biotech (CONCORDBIO) investor relations material

Executive summary

• Q1 FY 2027 revenue grew 26% year-on-year to INR 257 crore, driven by broad-based gains across immunosuppressants, anti-infectives, oncology, and antifungals, with new customers and products added.

• Export revenue surged 46% year-on-year, supported by expanded regulatory approvals, new product launches, and strong global demand.

• Commercial operations began at Stellon Biotech in the U.S., with the injectable facility ramping up and early sales and customer audits underway.

• Sustainability efforts were recognized with a silver medal from EcoVadis, placing the company among the top 15% globally assessed.

• Unaudited standalone and consolidated financial results for Q1 FY27 were approved, and Celliimune Biotech became a wholly owned subsidiary as of April 2, 2026.

Financial highlights

• Q1 FY27 revenue was INR 257 crore (₹25,748.90 lakhs consolidated), up from INR 204 crore (₹20,398.76 lakhs) in Q1 FY26, marking 26% growth.

• API segment revenue grew 42% to INR 219 crore; formulation revenue declined 23% to INR 39 crore.

• Gross margin improved to 78.9% (up 100 bps YoY); EBITDA was INR 82 crore (34% growth), with a margin of 32% (up 190 bps YoY).

• PAT stood at INR 58 crore (₹5,769.69 lakhs consolidated), up 31% YoY, with a PAT margin of 22.4% (up 80 bps YoY).

• Basic and diluted EPS (consolidated) for Q1 FY27 was ₹5.52, up from ₹4.21 in Q1 FY26.

Outlook and guidance

• Management expects growth to outpace historical rates, supported by a robust product pipeline, new launches, and ramp-up of injectables and Stellon Biotech.

• Targeting INR 3,000 crore revenue over five to six years, with INR 2,200 crore from APIs and INR 600-700 crore from formulations.

• Management continues to monitor regulatory changes, especially regarding new labour codes, and will adjust accounting as needed.